Pancreatic ductal adenocarcinoma(PDAC)is a malignancy characterized by an aggressive tumor behavior.The present analysis seeks to identify and analyze a cohort that meets criteria for"inflammatory"PDAC(IPDAC...Pancreatic ductal adenocarcinoma(PDAC)is a malignancy characterized by an aggressive tumor behavior.The present analysis seeks to identify and analyze a cohort that meets criteria for"inflammatory"PDAC(IPDAC).All patients who underwent a curative resection for PDAC at our institution between 1989 and 2015 were included in the retrospective analysis.Patients with histological proven adenocarcinoma and elevated C-reactive protein(CRP)(≥6 mg/L)serum concentrations,but no other suspicion of infection were included.We provide a matched control group with normal CRP serum levels from the same patient cohort.Thirty-six(6.8%)of 532 patients meet our criteria for an IPDAC group type.In-hospital(30 days)mortality was 13.9%in the IPDAC group vs 0%in the control group(P=.020).Median follow-up was 183.8 months(standard deviation[SD]=53.3,range 14.3-285.4).Median overall survival was 8.5 months(SD=16.8,range 0.3-89.6)in the IPDAC group and 24.8 months(SD=19.4,range 0.7-80.4)in the control group(P=.002).Patients indicating an IPDAC in our cohort had a significantly and clinical meaningful decreased overall survival and a higher perioperative morbidity and mortality.展开更多
文摘Pancreatic ductal adenocarcinoma(PDAC)is a malignancy characterized by an aggressive tumor behavior.The present analysis seeks to identify and analyze a cohort that meets criteria for"inflammatory"PDAC(IPDAC).All patients who underwent a curative resection for PDAC at our institution between 1989 and 2015 were included in the retrospective analysis.Patients with histological proven adenocarcinoma and elevated C-reactive protein(CRP)(≥6 mg/L)serum concentrations,but no other suspicion of infection were included.We provide a matched control group with normal CRP serum levels from the same patient cohort.Thirty-six(6.8%)of 532 patients meet our criteria for an IPDAC group type.In-hospital(30 days)mortality was 13.9%in the IPDAC group vs 0%in the control group(P=.020).Median follow-up was 183.8 months(standard deviation[SD]=53.3,range 14.3-285.4).Median overall survival was 8.5 months(SD=16.8,range 0.3-89.6)in the IPDAC group and 24.8 months(SD=19.4,range 0.7-80.4)in the control group(P=.002).Patients indicating an IPDAC in our cohort had a significantly and clinical meaningful decreased overall survival and a higher perioperative morbidity and mortality.
